Presair’s 200 new drug R&D project investment plan sincerely invites cooperation [Cooperation]

Protheragen has an investment plan for 200 new drug R&D projects, creating a new investment model. We sincerely invite cooperation. As a company focused on incubating early-stage new drug R&D projects, Protheragen adheres to advanced investment concepts and the entrepreneurial spirit of daring to venture and fight. It is determined to create a new investment model and will focus on investing in projects that have not entered the market and have no patents [or even no data, just brewing in the mind]. Presair plans to invest in 200 early-stage new drug research and development projects, with the investment amount for each project ranging from US$1 million to US$2 million. The expected amount can be exceeded based on the potential and innovation of the project. Preseri has no restrictions on the disease fields of the project. The drug forms it mainly focuses on include: antibodies, proteins, peptides, CAR-T, stem cells, cell therapy, gene therapy, oncolytic viruses, vaccines or small molecules. Presair hopes that under the general trend of China's creation and upgrading, it can work with entrepreneurial scientists to break through the difficulty of researching and developing domestic innovative drugs. China's pharmaceutical industry situation In 2018, the US FDA approved 59 new molecular entities for marketing, breaking a historical record. In China, the National Medical Products Administration (NMPA) has also approved an unprecedented 48 new drugs for marketing, but of these 48 new drugs, 38 are imported and 10 are domestically produced new drugs. From 2007 to 2017, China only approved less than 10 domestically independently developed chemical drugs and biological drugs. Correspondingly, seven locally developed Class 1.1 chemical drugs and biological drugs were approved in 2018. Although domestic innovation strength is growing, compared with international levels and capabilities, China's innovation still needs to be improved. China's innovative drug entrepreneurship situation During the "Thirteenth Five-Year Plan" period, China started from meeting people's livelihood needs and realizing industrial adjustment, and encouraged the continuous innovation and development of China's pharmaceutical industry. On the one hand, local governments introduced all-round support policies and increased subsidies for medical companies to develop the local pharmaceutical industry; on the other hand, the drug review and approval system continued to deepen reform, innovate the communication mechanism with drug applicants, and speed up the efficiency of innovative drug review. With the increase in capital injected into the pharmaceutical industry and the return of high-tech talents, China's pharmaceutical industry will have huge potential space and driving force for future development. In the pharmaceutical industry, compared with generic drugs and improved drugs, the research and development of innovative drugs has huge returns, but the research cycle is longer, the investment is larger, and the risks are higher. Most investment companies and investors are shunned by early-stage innovative drug projects. The current situation of domestic start-up companies with few financing channels, high thresholds and low amounts has forced many scientists to keep their entrepreneurial ideas in their minds. Even if they have many years of experience in new drug research and development and clear development ideas, scientists with entrepreneurial ideals will fall into the dilemma of where entrepreneurial funds come from and domestic policies are unclear. Purser's mission: Purser takes this investment plan as an opportunity to help new drug R&D scientists with entrepreneurial ideas and abilities take the first step in starting a business. We do not set any threshold for investment projects and do not have any rigid job requirements for entrepreneurial scientists. We provide the first pot of gold for scientists who are interested in entrepreneurship and provide the most relaxed entrepreneurial environment for scientists who suffer from lack of financial support. Presair's goal is to join hands with the world's outstanding biological experts and pharmaceutical experts to invest in the world's most novel and innovative drug research and development projects and seize the patent highlands in major global markets. At the same time, Presair sincerely invites colleagues in the industry to recommend outstanding projects, and the referral remuneration is 0.5% of the project valuation after the seed round investment. Friends from the investment community or industry are also welcome to inspect the projects we incubate, to invest or cooperate, and to join in the success! Presair recruits new Ph.D.s and senior experts in diagnosis, biopharmaceuticals, pharmacy, chemistry and other fields all year round, and industry friends are invited to enthusiastically recommend themselves or make recommendations. Reminder: Don’t rush to remit money or pay a deposit before seeing the real thing to avoid being cheated.